GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clever Leaves Holdings Inc (NAS:CLVR) » Definitions » ROE %

Clever Leaves Holdings (Clever Leaves Holdings) ROE % : -75.46% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Clever Leaves Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Clever Leaves Holdings's annualized net income for the quarter that ended in Dec. 2023 was $-20.34 Mil. Clever Leaves Holdings's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $26.95 Mil. Therefore, Clever Leaves Holdings's annualized ROE % for the quarter that ended in Dec. 2023 was -75.46%.

The historical rank and industry rank for Clever Leaves Holdings's ROE % or its related term are showing as below:

CLVR' s ROE % Range Over the Past 10 Years
Min: -116.92   Med: -55.39   Max: -36.8
Current: -54.23

During the past 5 years, Clever Leaves Holdings's highest ROE % was -36.80%. The lowest was -116.92%. And the median was -55.39%.

CLVR's ROE % is ranked worse than
86.1% of 1000 companies
in the Drug Manufacturers industry
Industry Median: 4.135 vs CLVR: -54.23

Clever Leaves Holdings ROE % Historical Data

The historical data trend for Clever Leaves Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clever Leaves Holdings ROE % Chart

Clever Leaves Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
-101.06 -36.80 -54.43 -116.92 -55.39

Clever Leaves Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -209.74 -42.30 -40.67 -64.59 -75.46

Competitive Comparison of Clever Leaves Holdings's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Clever Leaves Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Clever Leaves Holdings's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Clever Leaves Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Clever Leaves Holdings's ROE % falls into.



Clever Leaves Holdings ROE % Calculation

Clever Leaves Holdings's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-17.899/( (40.408+24.217)/ 2 )
=-17.899/32.3125
=-55.39 %

Clever Leaves Holdings's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-20.34/( (29.689+24.217)/ 2 )
=-20.34/26.953
=-75.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Clever Leaves Holdings  (NAS:CLVR) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-20.34/26.953
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-20.34 / 18.552)*(18.552 / 34.51)*(34.51 / 26.953)
=Net Margin %*Asset Turnover*Equity Multiplier
=-109.64 %*0.5376*1.2804
=ROA %*Equity Multiplier
=-58.94 %*1.2804
=-75.46 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-20.34/26.953
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-20.34 / -20.184) * (-20.184 / -19.648) * (-19.648 / 18.552) * (18.552 / 34.51) * (34.51 / 26.953)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0077 * 1.0273 * -105.91 % * 0.5376 * 1.2804
=-75.46 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Clever Leaves Holdings ROE % Related Terms

Thank you for viewing the detailed overview of Clever Leaves Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Clever Leaves Holdings (Clever Leaves Holdings) Business Description

Traded in Other Exchanges
N/A
Address
19-B Parque Industrial Tibitoc, Tocancipá, Cundinamarca, Bodega, Colombia, BC, CAN
Clever Leaves Holdings Inc is a producer of pharmaceutical and consumer cannabis brands. The company operates and has investments in Canada, Colombia, Germany, Portugal, and the United States. The company operates in two reportable segments, 1. The Cannabinoid operating segment: is comprised of the Company's cultivation, extraction, and commercialization of cannabinoid products. 2. Non-Cannabinoid operating segment is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements.
Executives
Andres Fajardo director, officer: President CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Julian Wilches officer: Chief Regulatory Officer CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Hague Henry R Iii officer: Chief Financial Officer 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
Gary M Julien director ONE LANDMARK SQUARE, 22ND FLOOR, STAMFORD CT 06901
William Muecke director C/O CLEVER LEAVES HOLDINGS, 6501 CONGRESS AVE, SUITE 240, BOCA RATON FL 33487
David Kastin officer: General Counsel C/O VITAMIN SHOPPE, INC., SECAUCUS NJ 07094
Kyle Detwiler director, officer: Chief Executive Officer CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017
George J Schultze 10 percent owner C/O SCHULTZE ASSET MANAGEMENT, LLC, 3000 WESTCHESTER AVENUE, PURCHASE NY 10577
Elisabeth H Demarse director CREDITCARDS.COM, 13809 RESEARCH BOULEVARD, SUITE 906, AUSTIN TX 78750
Etienne H. Deffarges director ACCRETIVE HEALTH, INC., 401 NORTH MICHIGAN AVENUE, SUITE 2700, CHICAGO IL 60611
Schultze Special Purpose Acquisition Sponsor, Llc 10 percent owner 800 WESTCHESTER AVENUE, SUITE 632, RYE BROOK NY 10573
Amit Pandey officer: Interim CFO CLEVER LEAVES HOLDINGS INC., 489 FIFTH AVENUE, 27TH FLOOR, NEW YORK NY 10017